NICE And The Cancer Drugs Fund – Can Observational Evidence Inform Funding Decisions In Oncology?

October 4, 2018 Danielle Twigg

 In April 2016, the CDF became a temporary reimbursement fund under the remit of NICE with the aim of collecting observational data to inform subsequent technology appraisals. This research aims to evaluate the use of real world evidence (RWE) collected through the CDF in subsequent re-appraisals.

Authors: Sean Walsh, Lok Wan Liu, Richard Macaulay

To find out more about this poster you can register to download it here after the ISPOR event.

 

Previous Article
RCT Not RWE: Two Year Report Card For The Cancer Drugs Fund Reforms
RCT Not RWE: Two Year Report Card For The Cancer Drugs Fund Reforms

Next Article
How To Use RWE To Optimize P&R Of New Health Technologies
How To Use RWE To Optimize P&R Of New Health Technologies